Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$56.55 - $66.59 $657,959 - $774,774
-11,635 Reduced 1.06%
1,081,843 $61.6 Million
Q4 2023

Feb 09, 2024

BUY
$52.16 - $64.19 $14.6 Million - $18 Million
280,559 Added 34.51%
1,093,478 $68.7 Million
Q3 2023

Nov 09, 2023

BUY
$57.77 - $65.93 $6.62 Million - $7.56 Million
114,676 Added 16.42%
812,919 $47 Million
Q2 2023

Aug 10, 2023

BUY
$60.95 - $75.51 $14.1 Million - $17.4 Million
230,966 Added 49.43%
698,243 $43.5 Million
Q1 2023

May 10, 2023

BUY
$70.23 - $86.01 $16.6 Million - $20.3 Million
235,750 Added 101.82%
467,277 $33.8 Million
Q4 2022

Feb 10, 2023

SELL
$67.18 - $84.11 $8.96 Million - $11.2 Million
-133,325 Reduced 36.54%
231,527 $18.6 Million
Q3 2022

Nov 10, 2022

BUY
$66.18 - $82.86 $15 Million - $18.8 Million
226,288 Added 163.31%
364,852 $24.3 Million
Q2 2022

Aug 10, 2022

BUY
$66.18 - $83.18 $1.97 Million - $2.48 Million
29,818 Added 27.42%
138,564 $10.5 Million
Q1 2022

May 11, 2022

SELL
$66.02 - $79.71 $23 Million - $27.8 Million
-349,078 Reduced 76.25%
108,746 $8.64 Million
Q4 2021

Feb 11, 2022

BUY
$63.34 - $74.11 $16.3 Million - $19.1 Million
257,474 Added 128.51%
457,824 $33.9 Million
Q3 2021

Nov 10, 2021

BUY
$68.67 - $84.02 $10.8 Million - $13.3 Million
157,724 Added 370.02%
200,350 $13.8 Million
Q2 2021

Aug 10, 2021

SELL
$79.87 - $87.53 $25.9 Million - $28.3 Million
-323,792 Reduced 88.37%
42,626 $3.58 Million
Q1 2021

May 12, 2021

SELL
$76.02 - $100.5 $460,681 - $609,030
-6,060 Reduced 1.63%
366,418 $29.8 Million
Q4 2020

Feb 10, 2021

SELL
$80.74 - $97.7 $4.18 Million - $5.06 Million
-51,799 Reduced 12.21%
372,478 $32.4 Million
Q3 2020

Nov 10, 2020

BUY
$85.07 - $109.69 $36.1 Million - $46.5 Million
424,277 New
424,277 $38.1 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $14.6B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Jupiter Asset Management LTD Portfolio

Follow Jupiter Asset Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jupiter Asset Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Jupiter Asset Management LTD with notifications on news.